Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC)

Charles J. Ryan, Walter M. Stadler, Bruce Roth, Douglass Hutcheon, Shauna Conry, Thomas Puchalski, Charles Morris, Eric J. Small

Research output: Contribution to journalArticlepeer-review

66 Scopus citations

Fingerprint

Dive into the research topics of 'Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC)'. Together they form a unique fingerprint.

Medicine & Life Sciences